Autentificare
NeuroPsy InfoHubÎnțelege · Sprijin · ProgresCere sprijin

Informație de încredere. Sprijin real.

Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.

Începe gratuitSunt părinteSunt specialist
Spațiu publicitar disponibil — bannerul mare de susSpațiu publicitar disponibil — bannerul mare de sus

Explorează temele

Caută tot →

Sănătate mintală și neurodezvoltare

AutismSpectrul autist și particularitățile asociate.223 de articole
ADHDAtenție, impulsivitate și hiperactivitate.202 articole
Sindrom DownDezvoltare și sprijin pentru sindromul Down.57 de articole
AnxietateÎngrijorare excesivă, tensiune, atacuri de panică.73 de articole
DepresieTristețe persistentă, lipsa energiei și a motivației.106 articole
AdicțiiDependențe de substanțe și comportamentale.135 de articole

Afecțiuni neurologice

DemențeBoala Alzheimer și alte forme de demență.73 de articole
AVC și AITAccident vascular cerebral și recuperare, la orice vârstă.64 de articole
Leziuni medulareLeziuni medulare, paraplegie și tetraplegie.55 de articole
EpilepsieCrize epileptice și managementul lor.127 de articole
ParkinsonBoala Parkinson și tulburări de mișcare.64 de articole
Scleroză multiplăScleroza multiplă și viața cu aceasta.71 de articole
Traumatisme cranio-cerebraleTraumatisme cranio-cerebrale și recuperare.81 de articole

Articole și ghiduri recomandate

PublicToțiPentru oricineSpecialiști
VârstăToate vârsteleCopiiTineriAdulțiVârstnici
StudiuEpilepsieÎncredere bună22.06.2026

Metformin's Anti-Seizure Mechanisms in Epilepsy: Pathways and Therapeutic Potential

This mechanistic review examines how metformin, an FDA-approved antidiabetic agent, may reduce seizures in treatment-resistant epilepsy through multiple pathways including AMPK activation, mTOR inhibition, and BDNF enhancement with neuroprotective effects. The authors propose metformin as a potential adjunctive agent to conventional anti-epileptic drugs, supported by preclinical evidence of reduced neuroinflammation and seizure severity.

StudiuEpilepsieÎncredere înaltă22.06.2026

The BrainDrugs-Epilepsy Study: Precision Medicine Biomarkers for Treatment Response Prediction

This prospective cohort study enrolls 350 patients (200 with first seizure, 150 newly diagnosed) to identify biomarkers predicting anti-seizure medication response and comorbid psychiatric/cognitive outcomes using EEG, MRI, PET imaging, and neuropsychological testing. Patients receive standardized treatment with lamotrigine or levetiracetam with 5-year follow-up monitoring clinical response, seizure recurrence, psychiatric symptoms, and quality of life.

StudiuEpilepsieÎncredere bună22.06.2026

Long-term outcomes in patients with negative prolonged ambulatory EEG: A 12-year follow-up study

A follow-up study of 47 patients with initially negative ambulatory EEG results found that 45% received an epilepsy diagnosis within 12 years, suggesting that negative EEG does not exclude epilepsy. Quality of life outcomes were associated with age, employment, and seizure history, highlighting the importance of comprehensive clinical evaluation beyond EEG testing alone.

StudiuEpilepsieÎncredere bună22.06.2026

Efficacy of Medium-Chain Triglyceride Enriched Diet Combined with Zonisamide in Dogs with Idiopathic Epilepsy: A Randomized Controlled Crossover Trial

A double-blinded, placebo-controlled crossover study evaluated MCT-enriched therapeutic diet combined with zonisamide in 7 dogs with idiopathic epilepsy over 6 months. While no significant difference in seizure frequency was found between diet groups overall, individual responses varied with 3 of 7 dogs achieving ≥50% seizure reduction during the MCT diet period, including one achieving seizure freedom.

StudiuEpilepsieÎncredere bună22.06.2026

Seizure-precipitating factors in Border Collies with idiopathic epilepsy: clinical case observations

This veterinary study examines seizure triggers in six Border Collies with idiopathic epilepsy, identifying breed-specific environmental and behavioral factors such as stress, lack of mental stimulation, social stressors, and external stimuli. Management strategies targeting identified triggers resulted in reduced seizure frequency or seizure freedom in these cases, demonstrating the clinical value of recognizing individualized precipitating factors in canine epilepsy.